Aurora Kinases-IN-3

• CAT Number: I042455
• CAS Number: 2840558-83-8
• Molecular Formula: C20H16F3N3O4
• Molecular Weight: 419.35
• Purity: ≥95%
• Synonyms: 3-[3-(2-methoxypyridin-4-yl)pyridin-2-yl]oxy-N-methyl-5-(trifluoromethoxy)benzamide
• InChI: InChI=1S/C20H16F3N3O4/c1-24-18(27)13-8-14(11-15(9-13)30-20(21,22)23)29-19-16(4-3-6-26-19)12-5-7-25-17(10-12)28-2/h3-11H,1-2H3,(H,24,27)
• InChIKey: NVMJCTQSUKIXBG-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=CC(=CC(=C1)OC(F)(F)F)OC2=C(C=CC=N2)C3=CC(=NC=C3)OC

Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10[1].
Aurora Kinases-IN-3 (Compound 15a) (40 nM; 6 h) disrupts localization of AURKB, MKLP1, and PLK at the spindle midzone to prevent spindle midzone microtubule assembly in RPE-MYCBCL2 cells. Aurora Kinases-IN-3 disrupts the localization of AURKB as early as anaphase, producing downstream consequences that blocked cytokinesis[1].
Aurora Kinases-IN-3 (1-10 μM; 3 days) shows wide spectrum of growth suppression in human cancer cell lines[1].
Aurora Kinases-IN-3 (Compound 15a) (50 mg/kg; oral; twice a day for 7 days) suppresses the growth of lung tumors in mice[1].

Reference

[1]. Lv G, et al. 2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114904.
 [Content Brief]